- Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas' newly created Genetic Regulation Primary Focus

Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy

- First-in-Class Antibody-Drug Conjugate Directed Against Nectin-4, a Protein Highly Expressed in Urothelial Tumors1,2 -

XTANDI is Now FDA-Approved for the Treatment of Metastatic Castration-Sensitive Prostate Cancer in Addition to Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer

Catherine Levitt and Charlotte Stanton named to key global and regional senior roles

Two exciting biotechs win a year of access to life-science incubator and in-house Astellas expertise to advance their early drug discovery research

Emerging mutations in patients with treatment resistance, from Phase 3 ADMIRAL study, will be focus of oral presentation

- Companies to Initiate Phase 3 Trial to Support Global Registrations -

Approval based on Asian PREVAIL study of men with metastatic castration-resistant prostate cancer

- Results were published online and in the October 31 print edition of the Journal -

- Four innovators awarded $200,000 in total grants and resources following live pitch event to a panel of judges that included celebrity entrepreneur Bill Rancic -

Approval follows accelerated assessment, orphan designation by European Medicines Agency

Financial Support for LabCentral Incubators Builds on Astellas' $1 Billion+ Investment in Boston's Life Science Community

- Finalists will present their ideas during a live pitch event

- Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response -

- Astellas named Working Mother "100 Best Company" for fifth consecutive year -

If approved by the European Commission, gilteritinib would represent one of the few advances in Europe for AML over the past 40 years(1)

- US Employees Support 16 Local Organizations for Changing Tomorrow Day 2019 -

- Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 -

Supporting pre-clinical scientific research: "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy

-Submission Based on Pivotal Phase 2 Trial Results Recently Presented at Annual Meeting of American Society of Clinical Oncology-

Glinski to Oversee US Sales for XTANDI

-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-

- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy[1] -

-Total Funds To Be Awarded Increased to $200,000; All Encouraged to Apply -

- Data Presented at the American Urological Association 2019 Annual Meeting -

- Study results will be presented at American Association for Cancer Research Annual Meeting 2019 -

- Companies Plan to Submit Biologics License Application Later This Year -

- Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women -

Joint Project Will Explore Enhancements to Patient Communication and Shared Decision-Making

Data to be presented at the 2019 Genitourinary Cancers Symposium

Acquisition adds clinical stage novel immuno-oncology programs to Astellas' oncology pipeline